



Nutritional support for balanced intestinal flora and protection against some infectious diarrhea

APPLICATIONS / BENEFITS

- Non-pathogenic probiotic yeast
- Promotes favorable environment for healthy gut flora
- Support for antibiotic-associated and traveler's diarrhea
- May be beneficial as adjunct to antibiotics

OVERVIEW

Saccharomyces boulardii is a non-pathogenic probiotic yeast that survives stomach acid to nourish the intestines, support the immune system and provide a favorable growth environment for the beneficial bacteria that support health and digestive comfort. Medical studies have shown the efficacy and safety of *S. boulardii* for a number of health conditions in both adults and children. These applications include prevention of antibiotic-related diarrhea, recurrent *C. difficile*-related diarrhea and colitis, traveler's diarrhea, acute bacterial and viral diarrhea, inflammatory bowels and irritable bowels.

S. boulardii acts as a temporary flora that quickly achieves high concentrations in the GI tract. It is one of the few yeasts that survives best at human body temperatures and is able to colonize and persist in the gut.

Healthy gut flora protects against some infectious diarrheas. Antibiotic-associated diarrhea (AAD) is an example, as antibiotics deplete and disrupt the normal flora, and the resulting diarrhea may be due to changes in short chain fatty acid metabolism. A severe form of AAD is due to *Clostridium difficile*, a pathogen that can cause severe diarrhea and colitis. Recurrent *C. difficile* diarrhea is difficult to treat successfully as one recurrence makes further recurrences more probable, likely because antibiotics are needed to treat and thus the fecal flora remains imbalanced. *Saccharomyces boulardii* may be beneficial as an adjunct to antibiotics.

Due to their fungal nature, the yeast cells of *S. boulardii* are antibiotic resistant.

Probiotic actions are strain specific and effectiveness of strains from the same species may be very different. *S. boulardii* is genetically and functionally distinct from brewer's yeast (*S. cerevisiae*) and different from pathogenic *Candida* species. Even though taxonomically assigned to the *S. cerevisiae* species, *S. boulardii* is characterized by a number of genetic features providing them to be more suitable to the intestinal environment. Patient One's *S. boulardii* strain is identified and verified through a combination of the most advanced genetic techniques.

Equally important to selecting an effective strain is selecting an effective preparation. Patient One's *S. boulardii* is obtained through a patented controlled-temperature, low-vacuum drying process. This technique preserves whole yeast cells and provides greater stability over time.

Provided in an acid-resistant vegetable capsule, Patient One *Saccharomyces boulardii* supplies a minimum of 5 Billion viable organisms per capsule and is stable at room temperature, making it convenient for travel.

RESEARCH

• Research has shown *S. boulardii* helps neutralize toxins. Pathogens such as *E. coli* and Salmonella irreversibly bind to the cell wall of *S. boulardii*, causing reduced binding to intestinal cells. *S. boulardii* effectively competes against the bacterium *C. difficile* which is known to flourish during antibiotic use and is often the cause of GI disturbances following antibiotic use. *S. boulardii* has also been shown to compete against Candida colonization.

• Researchers found that *S. boulardii* supports a healthy immune response and supports GI barrier function by maintaining a healthy inflammatory cycle in the GI tract. The double blind, placebo-controlled trial demonstrated that patients who took *S. boulardii* showed an increase in slgA levels and a subsequent reduction in CRP, an indicator of a balanced inflammatory response.

REFERENCES

1. L. Edwards-Ingram, P. Gitsham, N. Burton, G. Warhurst, I. Clarke, D. Hoyle, et al. Genotypic and physiological characterization of *Saccharomyces boulardii*, the probiotic strain of *Saccharomyces cerevisiae*. Applied and Environmental Microbiology. 2007;73(24):8667-8677
2. McFarland LV. Systematic review and meta-analysis of *Saccharomyces boulardii* in adult patients. World J Gastroenterol 2010;16(18): 2202-2222.
3. McCullough MJ, Clemons KV, Mccosker JH, Stevens DA. Species identification and virulence attributes of *Saccharomyces boulardii* (nom. invade.) Journal of Clinical Microbiology. 1998;36(12):3613-3617
4. Buts JP. Twenty-five years of research on *Saccharomyces boulardii* trophic effects: updates and perspectives.
5. McFarland LV. *Saccharomyces boulardii* is not *Saccharomyces cerevisiae*. Clin Infect Dis 1996;22(1): 200-1.
6. Surawicz CM. The microbiota and infectious diarrhea [Gastroenterologie clinique et biologique. 2010 Suppl 1:S2936 Epub 2010/10/05. Le microbiote dans les diarrhees infectieuses.
7. Czerucka D, Piche T, Rampal P. Review article: yeast as probiotics—*Saccharomyces boulardii*. Alimentary pharmacology & therapeutics. 2007;26(6):767-78. Epub 2007/09/05.
8. E. Im, C. Pothoulakis, Recent advances in *Saccharomyces boulardii* research] Gastroenterologie clinique et biologique. 2010 Suppl 1:S6270 Epub 2010/10/05. Progress recents dans la recherche sur *Saccharomyces boulardii*.
9. Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of *Saccharomyces boulardii* supplementation on *Helicobacter pylori* eradication rates and side effects during treatment. Alimentary pharmacology & therapeutics. 2010;32(9):1069-79.
10. Buts JP, Corthier G, Delmee M. *Saccharomyces boulardii* for *Clostridium difficile*- Associated Enteropathies in Infants. J Ped Gastroenterol Nutr 1993; 16:419-425.

11. Ozkan TB, Sahin E, Erdemir G, Budak F. Effect of *Saccharomyces boulardii* in children with acute gastroenteritis and its relationship to the immune response. J Int Med Res 2007; 35(2): 201-12.

12. Czerucka D, Piche T, Rampal P. Review article: yeast as probiotics—*Saccharomyces boulardii*. Aliment Pharmacol Ther 2007; 26(6):767-78.

Supplement Facts

Serving Size: 1 Capsule

Amount Per Serving

<i>Saccharomyces boulardii</i> (contains min. 5 billion CFUs per capsule at encapsulation)	250 mg*
--	---------

* Daily Value not established

Other Ingredients: rice flour, hypromellose (capsule), calcium palmitate

Free of: milk, egg, fish, peanuts, crustacean shellfish, soy, tree nuts, wheat and gluten. Free of ingredients derived from GMOs.

Suggested Use: Take 1 capsule twice daily as a dietary supplement, in divided doses between meals, or as directed by your health practitioner. Store in a cool, dry place. Keep desiccant in bottle to maintain freshness.

Caution: If you are pregnant, nursing, or taking any medications, consult your health practitioner before use. Discontinue use and consult your health practitioner if any adverse reactions occur. **Keep out of reach of children.**

Vegetarian

Gluten Free

Non-GMO

Vegetable Caps

The statements in this document have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

(631) 390-9669 info@patientoneformulas.com patientoneformulas.com

415 Oser Avenue, Suite Q1, Hauppauge, NY 11788

Patient One
MediNutritionals

© MediNutritionals Research LLC 2021